

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Data as of April 2, 2015**

Visit Adherence: Completion of Procedures¹ by Site

	Bronx Lebanon
Participants Enrolled	14
1. Pelvic Examination Required and Expected	51
Completed	51 (100.0%)
2. Perianal Examination Required and Expected	51
Completed	51 (100.0%)
3. Digital Rectal Examination Required and Expected	51
Completed	51 (100.0%)
4. Qualitative hCG Required and Expected	51
Completed	50 (98.0%)
Not Completed	1 (2.0%)
5. HIV-1 Serology Required and Expected	23
Completed	23 (100.0%)
6. PBMC for PK Required and Expected	37
Completed	37 (100.0%)
7. Plasma for PK Required and Expected	37
Completed	37 (100.0%)
8. Plasma Archive Required and Expected	14
Completed	14 (100.0%)
9. Vaginal Swab for Biomarkers Required and Expected	51
Completed	51 (100.0%)
10. Endocervical Swab for Biomarkers Required and Expected	51
Completed	51 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit Case Report Form (CRF), the procedures for that visit will not be included as expected.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Data as of April 2, 2015**

Visit Adherence: Completion of Procedures¹ by Site

	Bronx Lebanon
11. Vaginal Swab for PK Required and Expected	37
Completed	37 (100.0%)
12. Cervicovaginal Lavage Required and Expected	37
Completed	37 (100.0%)
13. Cervical Cytobrush for PK Required and Expected	27
Completed	27 (100.0%)
14. Vaginal Biopsies for PK Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)
15. Vaginal Biopsies for Gene Expression Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)
16. Vaginal Smear for Gram Stain Required and Expected	51
Completed	51 (100.0%)
17. Vaginal pH Required and Expected	51
Completed	51 (100.0%)
18. Rectal Sponge for PK Required and Expected	37
Completed	37 (100.0%)
19. Rectal Sponge for PD and Biomarkers Required and Expected	51
Completed	51 (100.0%)
20. Rectal Biopsies for PK Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit Case Report Form (CRF), the procedures for that visit will not be included as expected.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Data as of April 2, 2015**

Visit Adherence: Completion of Procedures¹ by Site

	Bronx Lebanon
21. Rectal Biopsies for Gene Expression Microarray Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)
22. Rectal Biopsy for Histology Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)
23. Rectal Biopsy for Proteomics Required and Expected	27
Completed	26 (96.3%)
Not Completed	1 (3.7%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit Case Report Form (CRF), the procedures for that visit will not be included as expected.